ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Ischaemia,Non-site specific necrosis and vascular insufficiency NEC,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
1,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
2,1,Embolism,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
3,1,Acidosis,Mixed acid-base disorders,Acid-base disorders,Metab,N
3,2,Disseminated intravascular coagulation,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
4,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,Y
5,1,Arteriosclerosis coronary artery,Coronary artery disorders NEC,Coronary artery disorders,Card,N
5,2,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
5,3,Coma,Coma states,Neurological disorders NEC,Nerv,N
5,4,Myocardial ischaemia,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
6,1,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
6,2,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
6,3,Coma,Coma states,Neurological disorders NEC,Nerv,N
7,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
7,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
8,1,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
8,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
8,3,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
9,1,Cardiac ventricular thrombosis,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
9,2,Haemodynamic instability,Non-site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
9,3,International normalised ratio decreased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
9,4,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
10,1,Brain oedema,Increased intracranial pressure disorders,Increased intracranial pressure and hydrocephalus,Nerv,Y
11,1,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
12,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
13,1,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
13,2,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
13,3,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
14,1,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,Y
15,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
16,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,Y
16,2,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
17,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
17,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
17,3,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
17,4,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
17,5,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
17,6,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
17,7,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
17,8,Skin hypertrophy,Skin hyperplasias and hypertrophies,Cornification and dystrophic skin disorders,Skin,N
17,9,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
17,10,Wrong product administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
18,1,Neurological decompensation,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
19,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
19,2,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
20,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
21,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
21,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
21,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
22,1,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
22,2,Cerebral infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
22,3,Facial paralysis,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
22,4,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
22,5,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
22,6,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
23,1,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
23,2,Oxygen saturation decreased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
23,3,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
23,4,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
24,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
24,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,Y
25,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
26,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
26,2,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
26,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
26,4,Flushing,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
26,5,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
26,6,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
26,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
26,8,Oxygen saturation decreased,Blood gas and acid base analyses,"Metabolic, nutritional and blood gas investigations",Inv,N
26,9,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
27,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
27,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,Y
28,1,Infusion site extravasation,Infusion site reactions,Administration site reactions,Genrl,N
28,2,Infusion site necrosis,Infusion site reactions,Administration site reactions,Genrl,N
28,3,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
29,1,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
30,1,Disseminated intravascular coagulation,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
30,2,Purpura fulminans,Purpura and related conditions,Skin vascular abnormalities,Skin,N
30,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
30,4,Therapeutic product effect decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
30,5,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
31,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
31,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
31,3,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
31,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
31,5,Respiratory distress,Breathing abnormalities,Respiratory disorders NEC,Resp,N
31,6,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
32,1,Cerebral thrombosis,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
33,1,Catheter site related reaction,Implant and catheter site reactions,Administration site reactions,Genrl,N
33,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
33,3,Extravasation,General signs and symptoms NEC,General system disorders NEC,Genrl,N
33,4,Inflammation,Inflammations,General system disorders NEC,Genrl,N
33,5,Injection site discomfort,Injection site reactions,Administration site reactions,Genrl,N
33,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
33,7,Skin discolouration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
34,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
34,2,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
34,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
34,4,Thrombotic microangiopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
35,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
35,2,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
36,1,Blood pressure diastolic increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
36,2,Intrapericardial thrombosis,Pericardial disorders NEC,Pericardial disorders,Card,N
37,1,Body temperature decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
37,2,Unresponsive to stimuli,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
38,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
38,2,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
38,3,Coma,Coma states,Neurological disorders NEC,Nerv,N
38,4,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
38,5,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
38,6,Hypoxia,Conditions associated with abnormal gas exchange,Respiratory disorders NEC,Resp,N
38,7,Respiratory distress,Breathing abnormalities,Respiratory disorders NEC,Resp,N
38,8,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
38,9,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
38,10,Underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
39,1,Coagulation time prolonged,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
40,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
41,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
41,2,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
42,1,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
42,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
42,3,Necrotising fasciitis,Muscle and soft tissue infections,Infections - pathogen unspecified,Infec,Y
42,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
43,1,Blood pressure systolic increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
43,2,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
43,3,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
43,4,Feeling cold,Feelings and sensations NEC,General system disorders NEC,Genrl,N
43,5,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
43,6,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
43,7,Wheezing,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
44,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
44,2,Coagulopathy,Coagulopathies,Coagulopathies and bleeding diatheses (excl thrombocytopenic),Blood,N
45,1,Splenectomy,Lymphoid tissue therapeutic procedures,Haematological and lymphoid tissue therapeutic procedures,Surg,N
45,2,Syncope,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
46,1,Accidental underdose,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
46,2,Cerebral mass effect,Structural brain disorders NEC,Structural brain disorders,Nerv,N
46,3,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
46,4,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
47,1,Drug ineffective for unapproved indication,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
47,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
48,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
48,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
49,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
49,2,No adverse event,Adverse effect absent,General system disorders NEC,Genrl,N
49,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
50,1,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
50,2,SARS-CoV-2 test positive,Virus identification and serology,Microbiology and serology investigations,Inv,N
51,1,Odynophagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
52,1,Heavy menstrual bleeding,Menstruation with increased bleeding,Menstrual cycle and uterine bleeding disorders,Repro,N
53,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
54,1,Cardiac ventricular thrombosis,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
55,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
56,1,Cardiac ventricular thrombosis,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,Y
56,2,Coronary artery embolism,Coronary artery disorders NEC,Coronary artery disorders,Card,N
56,3,Embolic cerebellar infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
56,4,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
57,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
57,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
58,1,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
59,1,Device issue,Device issues NEC,Device issues,Prod,N
60,1,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
60,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,Y
